A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease (COPD) Over 3 Years of Treatment
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease (COPD) Over 3 Years of Treatment
The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.
A multicenter, randomized, double-blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment.
Inclusion criteria:
Exclusion criteria:
Sepuldeva, California 91343, United States
Downington, Pennsylvania 19335, United States
Buenos Aires, Buenos Aires 1272, Argentina
Wangfujing, Beijing, 100730, China
Ostrava - Fifejdy, 728 80, Czechia
Silkenborg, DK-8600, Denmark
Kohtal-Jdrve, 31 025, Estonia
Corbeil Essonne, 91100, France
Maroussi, Athens, 11526, Greece
Papagos/Athens, 15669, Greece
Fossvogur. Reykjavic, 108, Iceland
Wellington South, 6002, New Zealand
Orihuela/Alicante, 03314, Spain
Vigo/Pontevedra, 36200, Spain
Vizcaya, 48902, Spain
Tau-Yuan County, 333, Taiwan